WHO WE ARE


Dr. Jerome

Dr. Jerome H. Kim, International Vaccine Institute
Dr. Jerome H. Kim, International Vaccine Institute, Seoul, Republic of Korea. Dr. Kim has long experience in vaccine development for poverty associated infectious diseases. He has more recently been working on tools that will facilitate the transition of vaccines over gaps in the development process and into implementation, including Strep A, HIV and non-typhoidal salmonella.
Chair of the SAVAC Executive Committee

For more information, please visit https://www.ivi.int/.


Prof. Andrew Steer

Prof. Andrew Steer, Murdoch Children's Research Institute
Prof. Andrew Steer, Murdoch Children's Research Institute, Melbourne, Australia. Prof. Steer has been a leading advocate for Group A Strep (GAS) vaccines, has led work on the molecular epidemiology of the disease, and recently has begun to develop a human challenge model for GAS pharyngitis.
Co-Chair of the SAVAC Executive Committee

For more information, please visit https://www.mcri.edu.au/.


Prof. Jonathan Carapetis

Prof. Jonathan Carapetis, Telethon Kids Institute, University of Western Australia
Prof. Jonathan Carapetis is the Director of the Telethon Kids Institute in Perth, Western Australia, an infectious diseases consultant physician at the Perth Children’s Hospital and a Professor at the University of Western Australia. Prof. Carapetis is a leader in the study of Group A streptococcus epidemiology and disease burden. He has long been an advocate for the development of GAS vaccines.

For more information, please visit https://www.telethonkids.org.au/.


Prof. David Bloom

Prof. David Bloom, Harvard School of Public Health
Prof. David Bloom, Harvard School of Public Health, USA. Prof. Bloom is a noted health economist and in particular has led in the development of analyses looking at the "whole benefit" (inclusive of social benefit) of vaccination. He will lead the health economic part of the full public value of vaccine (FPVV)

For more information, please visit https://www.hsph.harvard.edu/.


Dr. David Kaslow

Dr. David Kaslow, PATH
Dr. David Kaslow, as vice president of PATH Essential Medicines, supports PATH’s Drug Innovation and Access Initiative and PATH’s Center for Vaccine Innovation and Access (CVIA). He has over 35 years of research and development experience in product development and introduction including in the US government, biotech, multi-national pharma, and non-profit sectors. He serves on a number of advisory committees, including WHO Product Development of Vaccines Advisory Committee.

Address: 2201 Westlake Avenue, Suite 200 Seattle, WA 98121, USA
Mailing address: PO Box 900922 Seattle, WA 98109
Phone: 206.285.3500
Fax:206.285.6619
Email: info@path.org
Web: https://www.path.org/.


Prof. Shiranee Sriskandan

Prof. Shiranee Sriskandan, Imperial College
Prof. Shiranee Sriskandan, Professor of Infectious Diseases at Imperial College London and a Clinical Infectious Diseases consultant at Hammersmith Hospital, is a noted scientist in the study of GAS pathogenesis. She leads the gram-positive pathogenesis research group at Imperial College within the Department of Infectious Disease and will bring both an infectious diseases and basic sciences background to the consortium committee.

For more information, please visit https://www.imperial.ac.uk/


Prof. Liesl Zühlke

Prof. Liesl Zühlke, University of Cape Town
Prof. Liesl Zühlke is a Paediatric Cardiologist at the Red Cross War Memorial Children’s Hospital and jointly affiliated to the Division of Cardiology, Department of Medicine, University of Cape Town. She directs the Childrens Heart Disease Research Unit and is President of Reach, the scientific and technical support for Global RHD programs.

For more information, please visit https://www.uct.ac.za/


Prof. Ewin J. Asturias

Prof. Ewin J. Asturias, University of Colorado
Edwin J. Asturias, MD, is a Professor of Pediatrics at the University of Colorado School of Medicine and a Professor of Epidemiology at the Colorado School of Public Health, in Aurora, Colorado, and holds the Jules Amer Chair in Community Pediatrics at Children’s Hospital Colorado. He will lead the working group on Strep A vaccine safety in the consortium.

Prof. Balram Bhargava, Indian Council of Medical Research & National Technical Advisory Group on Immunisation.
Prof. Bhargava is the Director General of the Indian Council of Medical Research and is the co-Chair of the Indian technical advisory group on immunisation. He will provide expertise from the national implementation perspective.

For more information, please visit https://www.icmr.nic.in/.



The International Vaccine Institute (IVI) is the world’s only non-profit international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997 with a United Nations treaty, IVI operates as an independent international organization under the treaty signed by 35 countries and the World Health Organization. The International Vaccine Institute (IVI) is dedicated to enabling the world's most vulnerable people to have full, productive lives by accelerating R&D for critical vaccines with partners around the globe. IVI fulfills this mission by developing and delivering vaccines against infectious diseases with limited commercial potential yet high global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, strep A, HAV, HPV, TB, HIV, MERS-CoV and AMR. The Institute conducts research in more than 30 countries throughout Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea.

 

IVI SAVAC Team - From left to right: Francois Belin, Vittal Mogasale, Hyeong-Won Seo (Developer of the SAVAC website), Jerome Kim, Alice (Eunju) Lee, Jungseok Lee, Mi Hwa Ka, Chloe Sye Lim Hong, Somyoung Cho, Prerana Parajulee



Jerome H. Kim, Principal Investigator

Jean-Louis Excler, Project Lead



For more information, please visit https://www.ivi.int/.



The Murdoch Children's Research Institute (MCRI) is the largest child health research institute in Australia and one of the top three worldwide. Our team of more than 1500 researchers is dedicated to making discoveries to prevent and treat childhood conditions. Many of our researchers are also clinicians at the Royal Children’s Hospital in Melbourne, where the institute is based.

The MCRI has a strong focus on global health, and is a founding partner of Melbourne Children’s Global Health, an initiative that aims to reduce inequity and improve child and adolescent health in disadvantaged populations globally.

Researchers in the Infection and Immunity Theme at MCRI work to address important infectious diseases that impact children both locally and globally. Rotavirus was discovered at MCRI, and a vaccine developed at the institute is now being deployed in a number of countries. The research topics within the theme are broad, with a strong track record in vaccinology (vaccine discovery, vaccine clinical trials and evaluation, controlled human infection studies and vaccine safety) and neglected tropical diseases (Strep A, rheumatic fever, scabies and other parasitic diseases).


For more information, please visit https://www.mcri.edu.au/.




The Telethon Kids Institute is based within the Perth Children’s Hospital, Western Australia, and is one of the largest, and most successful medical research institutes in Australia, comprising a dedicated and diverse team of more than 700 staff and students. Telethon Kids brings together community, researchers, practitioners, policy makers and funders, who share their vision to improve the health and development of children through excellence in research, and the application of that knowledge. The Institute is headed by leading paediatrician and infectious diseases expert Professor Jonathan Carapetis AM, who also leads an extensive program of research into Strep A and Rheumatic Heart Disease (RHD). The RHD team works with the community, governments and the health sector - both locally and internationally - to investigate ways to prevent RHD as well as better treatments for those living with RHD. Telethon Kids is a founding member of the END RHD Alliance and is leading the development of the RHD Endgame Strategy, in collaboration with communities, to eliminate RHD by 2031.


For more information, please visit https://www.telethonkids.org.au/.




The preferred description of PATH follows below: PATH is a global organization that works to accelerate health equity by bringing together public institutions, businesses, social enterprises, and investors to solve the world’s most pressing health challenges. With expertise in science, health, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales solutions—including vaccines, drugs, devices, diagnostics, and innovative approaches to strengthening health systems worldwide.


Contact Information

Address: 2201 Westlake Avenue, Suite 200 Seattle, WA 98121, USA
Mailing address: PO Box 900922 Seattle, WA 98109
Phone: 206.285.3500
Fax:206.285.6619
Email: info@path.org
Web: https://www.path.org/.




For more information, please visit https://www.icmr.nic.in/.


Shift Health brings a science mindset to strategy consulting for the health research and innovation ecosystem. We are inspired by our work with clients in addressing the healthcare needs of underserved or vulnerable populations across the globe. Shift Health occupies a unique niche within a diverse international network of government development agencies, private foundations and charitable organizations, researchers focused on infectious, emerging and neglected diseases, and industry players dedicated to overcoming commercial hurdles and bringing their resources and technologies to bear.

Shift Health team members supporting development of Strep A vaccine business case:

Dr. Ryan Wiley (President), Dr. Anne Mullin (Engagement Leader), Dr. Don Walkinshaw (Senior Consultant), Dr. Marni Williams (Consultant), Dr. Tanya Scarapicchia (Analyst) and Dr. Meghan Wright (Analyst)



Dr. Ryan Wiley, President

Dr. Anne Mullin, Engagement Leader

Dr. Don Walkinshaw, Senior Consultant



For more information, please visit www.shifthealth.com or e-mail (info@shifthealth.com).




For more information, please visit https://www.uct.ac.za/



Harvard T.H. Chan School of Public Health brings together dedicated experts from many disciplines to educate new generations of global health leaders and produce powerful ideas that improve the lives and health of people everywhere.

As a community of leading scientists, educators, and students from around the world, we work together to take innovative ideas from the laboratory to people’s lives—not only making scientific breakthroughs, but also working to change individual behaviors, public policies, and health care practices to create a healthier world.


For more information, please visit https://www.hsph.harvard.edu/.





For more information, please visit https://www.imperial.ac.uk/




Dr. Johan Vekemans

Dr. Johan Vekemans, WHO IVR
Dr Johan Vekemans is a Medical Officer at the Initiative for Vaccine Research, World Health Organization (WHO IVR). He acts as vaccine R&D focal point for malaria, tuberculosis and HIV, in addition to other disease areas including group A Streptococcus. He will contribute as observer and coordinator for SAVAC activities providing normative guidance, and stewardship of the PPC and R&D Roadmap.

For more information, please visit https://www.who.int/immunization/en/.